Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427553 | 0.83 | MEN1 (0.44) | LTA4HOPRK1MEN1KMT2A | |
| SCHEMBL16215655 | 0.83 | MEN1 (0.44) | DRD2DRD4DRD3LTA4HOPRK1 | |
| SCHEMBL30833222 | 0.83 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL3880869 | 0.83 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL3880873 | 0.83 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL694189 | 0.82 | CHRM2 (0.62) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL16766586 | 0.82 | CHRM2 (0.62) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL16766562 | 0.82 | CHRM2 (0.62) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL13993541 | 0.82 | CHRM2 (0.62) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL5971566 | 0.80 | DRD2 (0.54) | DRD2DRD4DRD3SLC6A2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1525201-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | Pfizer Products Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009588-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | DRD2 475/4885DRD4 634/4885DRD3 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.